NVX-CoV2705

BIOLOGICAL2 trials

Sponsors

Sanofi, Novavax

Conditions

COVID-19SARS-CoV-2 InfectionSars-CoV-2 Infection

Phase 3

Safety and Immunogenicity of NVX-CoV2705

CompletedNCT07079670

SanofiCOVID-19, SARS-CoV-2 Infection

Start: 2025-10-09End: 2026-05-11Updated: 2026-06-05

Phase 4

Efficacy and Safety of NVX-CoV2705

Active, not recruitingNCT07086222

NovavaxCOVID-19, Sars-CoV-2 Infection

Start: 2025-11-20End: 2026-11-18Updated: 2026-05-08